Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The following is a summary of "BCL-2 dependence is a favorable predictive marker of response to therapy for chronic ...

Mar. 10, 2025 — Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

CREsted is a Python package for training sequence-based deep learning models on scATAC-seq data, for capturing enhancer code and for designing cell type-specific sequences.

2月21日A股收盘，百济神州以3107亿元市值，反超恒瑞医药的3080亿元,终结后者长达15年的“医药一哥”地位，被行业视为“历史性时刻”。 其中，百悦泽是治疗血液肿瘤的BTK抑制剂，2019年在美国上市，此后销量暴涨，2023年更是达到13亿美元，成为中国首个超10亿美元的重磅药物。

gene therapy Zolgensma with simpler administration – should be forthcoming before the end of this year. 2025 should see results for ianalumab in Sjogren's syndrome and as a second-line therapy ...

For chronic lymphocytic leukemia (CLL), the most common type in adults, the Phase III AMPLIFY trial found that a fixed-duration combination of two pills—the BTK inhibitor Calquence (acalabrutinib) and ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia. Corresponding author Helga Simon-Molas, PhD, of the University of ...